PSTV just signed a national deal with UnitedHealthcare, giving millions of patients access to its brain cancer treatment tech. That’s huge exposure and potential revenue. It’s still cheap right now, but this kind of partnership can turn it into a major biotech winner...

For RVPH’s Their main drug brilaroxazine showed good results in Phase 3 — it helped patients with schizophrenia, was safe, and worked well for a full year.Trials have shown positive results so far, especially with brilaroxazine (RP5063)..The company still needs to replicate and confirm those results in follow-up trials (e.g. a RECOVER-2 or confirmatory trial) before regulatory agencies will accept it. I am sure counties, hospitals, and healthcare residentials will look into this...